| Market Opportunity | $69.9MAnnual US Sales |
|---|---|
| Market Cap | ₹65,840.2 CrLarge Cap |
| Revenue TTM | ₹17,736.5 CrOperating |
| RSI | 58.93Neutral Zone |
Key highlights
- Launched three presentations including 1,000 mg/10 mL and 5,000 mg/50 mL vials
- Includes a 10,000 mg/100 mL Pharmacy Bulk Package for institutional use
- Targets a total addressable annual market of $69.9 million as per June 2026 data
- Product is bioequivalent to Fresenius Kabi USA's reference listed drug NDA 208418
- Reinforces the company's strategic focus on sustainable and differentiated injectables
The Product — What It Is
Calcium Gluconate Injection USP is a mineral supplement indicated for the treatment of hypocalcemia in conditions where a rapid increase in plasma calcium levels is required. Glenmark's new offering includes 100 mg/mL concentrations available in both single-dose vials and specialized pharmacy bulk packages. These formulations are designed to meet rigorous hospital standards and are therapeutically equivalent to the reference listed drug from Fresenius Kabi USA.
The inclusion of diverse dosage formats ensures that healthcare providers have access to versatile options for patient care across various clinical environments in North America.
Commercial Opportunity
- Addresses an annual market valued at approximately $69.9 million according to IQVIA sales data for the period ending June 2026
- Positions the company to capture share in the competitive U.S. institutional and hospital supply chain
- Provides a bioequivalent alternative to NDA 208418, expanding the available supply for critical mineral supplements
- Leverages existing distribution networks to reach over 80 countries through a global commercial footprint
Strategic Expansion
The launch of Calcium Gluconate Injection USP marks another important step in strengthening Glenmark’s U.S. injectables business and expanding our hospital portfolio. It reflects the disciplined execution of our strategy to build a differentiated and sustainable injectables business.
Business Overview
Glenmark Pharmaceuticals Limited is a global, research-led pharmaceutical entity with 11 world-class manufacturing facilities spanning four continents. The company operates six cutting-edge R&D centres and maintains a diversified portfolio across branded, innovative, generic, and consumer health segments. Its primary therapeutic focuses include respiratory, dermatology, and oncology.
By expanding its U.S. injectables portfolio, Glenmark continues to target institutional needs and supply resilience within the healthcare system, building on its position among the top 100 biopharmaceutical companies globally by pharmaceutical sales.
| Share price | ₹2332.9 |
|---|---|
| Market capitalisation | ₹65,840.20 Cr |
| Revenue (annual) | ₹16,982.51 Cr |
| Net profit (annual) | ₹1,361.85 Cr |
| Revenue (latest quarter) | ₹4,018.48 Cr+6.57% vs previous quarter |
| Net profit (latest quarter) | ₹482.92 Cr+60.22% vs previous quarter |
| P/E (TTM) | 36.62×Sector 45.65× |
| Promoter holding | 46.65%0.00% QoQ |
| FII holding | 20.89%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Glenmark Pharmaceuticals Limited announcing the launch of Calcium Gluconate Injection USP in the United States. Market figures from a third-party data provider.
